心欣舒胶囊联合环磷腺苷葡胺治疗病毒性心肌炎的临床研究

目的探讨心欣舒胶囊联合环磷腺苷葡胺治疗病毒性心肌炎的临床疗效。方法选取2015年3月—2016年3月延安大学附属医院收治的病毒性心肌炎患者76例,随机分为对照组和治疗组,每组各38例。对照组静脉滴注注射用环磷腺苷葡胺,180 mg加入到5%葡萄糖溶液250 m L,1次/d。治疗组在对照组基础上口服心欣舒胶囊,5粒/次,3次/d。两组患者均治疗30 d。观察两组的临床疗效,比较血清心肌酶谱和血清学指标的变化。结果治疗后,对照组和治疗组的总有效率分别为78.95%、94.74%,两组比较差异有统计学意义(P0.05)。治疗后,两组患者CK-MB、CPK、LDH和AST均明显降低,同组治疗前后差异有统计学意义(P0.05);且治疗组这些观察指标的降低程度明显低于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,两组患者TNF-α和IL-6水平明显降低,而SOD水平明显升高,同组治疗前后差异有统计学意义(P0.05);且治疗组这些观察指标的改善程度明显优于对照组,两组比较差异具有统计学意义(P0.05)。结论心欣舒胶囊联合环磷腺苷葡胺治疗病毒性心肌炎具有较好的临床疗效,可明显减轻心肌细胞损伤,降低炎症反应,具有一定的临床推广应用价值。

Clinical study on Xinxinshu Capsules combined with meglumine adenosine cyclophosphate in treatment of viral myocarditis

Objective To investigate the clinical effect of the treatment of Xinxinshu Capsules combined with meglumine adenosine cyclophosphate in treatment of viral myocarditis. Methods Patients (76 cases) with viral myocarditis in Yan’an University Affiliated Hospital from March 2015 to March 2016 were randomly divided into the control and treatment groups, and each group had 38 cases. Patients in the control group were iv administered with Meglumine Adenosine Cyclophosphate for injection, 180 mg added into glucose solution 250 mL, once daily. Patients in the treatment group were po administered with Xinxinshu Capsules on the basis of the control group, 5 grains/time, three times daily. After treatment, the clinical efficacies were evaluated, and the changes of serum myocardial enzyme spectrum and serological indexes in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 78.95%and 94.74%, respectively, and there was difference between two groups (P<0.05). After treatment, CK-MB, CPK, LDH, and AST in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of TNF-αand IL-6 in two groups were significantly decreased, but the levels of SOD in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). Conclusion Xinxinshu Capsules combined with meglumine adenosine cyclophosphate has clinical curative effect in treatment of viral myocarditis, and can obviously reduce myocardial cell injury and inflammatory reaction, which has a certain clinical application value.